Zobrazeno 1 - 10
of 242
pro vyhledávání: ''
Autor:
Christiane Mühle, Valery Grinevich, Johannes Kornhuber, Patrick Bach, Christian Weinland, Falk Kiefer, Bernd Lenz, Iulia Zoicas
Publikováno v:
European Neuropsychopharmacology. 51:55-67
Alcohol use disorder (AUD) is a severe illness, for which we lack sufficient mechanistic understanding. Preliminary evidence associates AUD with the oxytocin (OXT) system. Here we investigated alterations in endogenous OXT blood concentrations in pat
Autor:
Claudia da Costa Leite, Márcio Gerhardt Soeiro-de-Souza, E. Scotti-Muzzi, Fernando Fernandes, Rodrigo Machado-Vieira, R. T. De Sousa, Maria Concepcion Garcia Otaduy
Publikováno v:
European Neuropsychopharmacology. 49:93-100
The diagnosis and treatment of bipolar depression (BDep) poses complex clinical challenges for psychiatry. Proton magnetic resonance spectroscopy (1H-MRS) is a useful imaging tool for investigating in vivo levels of brain neuro-metabolites, critical
Autor:
Nisha Singh, Amanda Kiemes, Diana Cash, Gemma Modinos, Anthony C. Vernon, Alba Peris-Yague, Marie-Caroline Cotel
Publikováno v:
European Neuropsychopharmacology. 41:106-117
Post-mortem studies suggest that schizophrenia is associated with abnormal expression of specific GABAA receptor (GABAAR) α subunits, including α5GABAAR. Positron emission tomography (PET) measures of GABAAR availability in schizophrenia, however,
Autor:
Yukihiro Noda, Yuko Arioka, Mizuki Uchida, Akihiro Mouri, Takayoshi Mamiya, Norio Ozaki, Shokuro Yamada, Shinji Kitagaki, Itaru Kushima, Akira Yoshimi, Sakika Goto
Publikováno v:
European Neuropsychopharmacology. 41:92-105
The smoking incentive in patients with schizophrenia (SCZ) depends on stimulation of nicotinic acetylcholine receptors (nAChRs) in the central nervous system. To detect potential predictor genes for nicotine responses in SCZ, we explored common facto
Publikováno v:
European Neuropsychopharmacology. 31:131-144
Amitriptyline is prescribed for treating the symptoms of neuroinflammatory disorders including neuropathic pain and fibromyalgia. As amitriptyline has evidence of modulating the neuroimmune interface; the effects of amitriptyline treatment on T-cell
Autor:
Jakob Unterholzner, Wolfgang Wadsak, Marius Hienert, Markus Hartenbach, Gregor Gryglewski, Alexander Kautzky, Andreas Hahn, Rupert Lanzenberger, Thomas Vanicek, Leo Silberbauer, Paul Michenthaler, Neydher Berroterán-Infante, Theresa Balber, Lucas Rischka, Godber M Godbersen, Eva-Maria Klebermass, Murray B. Reed, Verena Pichler, Markus Mitterhauser, Siegfried Kasper, Marcus Hacker, Manfred Klöbl, G.M. James, Chrysoula Vraka, E. Winkler-Pjrek
Publikováno v:
European Neuropsychopharmacology. 29:711-719
Pharmacological imaging of the effects of selective serotonin reuptake inhibitors (SSRI) may aid the clarification of their mechanism of action and influence treatment of highly prevalent neuropsychiatric conditions if the detected effects could be r
Autor:
Matthias Reimold, Andrea Kobiella, Michael N. Smolka, Marcella Rietschel, Andreas Heinz, Gerald Reischl
Publikováno v:
European Neuropsychopharmacology. 29:171-178
Although preclinical studies clearly indicate an effect of 5-HTTLPR genotype on 5-HT transporter (5-HTT) expression, studies in humans provided inconclusive results, hypothetically due to environmental factors and differences in individual behavior.
Autor:
Purificación López-Peña, C. Bermúdez-Ampudia, Eduard Vieta, Mónica Martínez-Cengotitabengoa, Ana González-Pinto
Publikováno v:
European Neuropsychopharmacology. 28:1351-1359
To critically examine the effectiveness of lithium in preventing depressive symptoms (mixed and depressive episodes) in real life settings, taking into account adherence to drug treatment and its implications for the clinical costs of the disease. Ov
Autor:
Bronwyn Lester, Peter D. Drummond
Publikováno v:
European Neuropsychopharmacology. 28:1284-1288
The aim of this study was to determine whether loratadine, a selective inverse agonist of peripheral histamine H1 receptors, would reduce emotional blushing. Loratadine (10 mg) or placebo was administered orally one hour before 31 healthy participant
Publikováno v:
European Neuropsychopharmacology. 28:630-642
Activating the endocannabinoid system has become a major focus in the search for novel therapeutics for anxiety and deficits in fear extinction, two defining features of PTSD. We examined whether chronic treatment with the fatty acid amide hydrolase